Shanghai Kehua Bio-engineering Co Ltd (002022):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Shanghai Kehua Bio-engineering Co Ltd (002022) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9997
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:18
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:中国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Shanghai Kehua Bio-engineering Co Ltd (KHB) is a medical device company that develops, manufactures and markets in vitro diagnostic devices and related products. The company’s major product portfolio includes enzyme immunoassay kits, clinical chemistry reagents, PCR kits, rapid test kits, chemiluminescence reagents; and laboratory instruments such as clinical chemistry analyzers, electrolyte analyzers, microplate readers, nucleic acid extractors and automatic chemiluminescence analyzers. It is one of the global suppliers of WHO, UNICEF, PEPFAR, and the Clinton HIV/AIDS Initiative. The company has sales supports facilities in major cities in China and it markets its products in China and across the world through distributors. KHB is headquartered in Shanghai, China.

Shanghai Kehua Bio-engineering Co Ltd (002022) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Shanghai Kehua Bio-engineering Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Shanghai Kehua Bio-engineering Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Shanghai Kehua Bio-engineering Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Shanghai Kehua Bio-engineering Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Shanghai Kehua Bio-engineering Co Ltd, Medical Devices Deals, 2012 to YTD 2018 9
Shanghai Kehua Bio-engineering Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Shanghai Kehua Bio-engineering Co Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Shanghai Kehua to Acquire Diagnostic Assets from Altergon Italia 11
Acquisition 12
Shanghai Kehua Bio-Engineering Plans to Acquire 55% Stake in Guangdong-Based Biotechnology Company for USD19.3 Million 12
KHB Shanghai Kehua Bio-Engineering Acquires Technogenetics USD20.6 Million 13
Shanghai Kehua to Acquire Technogentics from Bouty Healthcare 14
Shanghai Kehua Bio-engineering Co Ltd – Key Competitors 15
Shanghai Kehua Bio-engineering Co Ltd – Key Employees 16
Shanghai Kehua Bio-engineering Co Ltd – Locations And Subsidiaries 17
Head Office 17
Other Locations & Subsidiaries 17
Appendix 18
Methodology 18
About GlobalData 18
Contact Us 18
Disclaimer 18

List of Tables
Shanghai Kehua Bio-engineering Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Shanghai Kehua Bio-engineering Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Shanghai Kehua Bio-engineering Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Shanghai Kehua Bio-engineering Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Shanghai Kehua Bio-engineering Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Shanghai Kehua Bio-engineering Co Ltd, Medical Devices Deals, 2012 to YTD 2018 9
Shanghai Kehua Bio-engineering Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Shanghai Kehua to Acquire Diagnostic Assets from Altergon Italia 11
Shanghai Kehua Bio-Engineering Plans to Acquire 55% Stake in Guangdong-Based Biotechnology Company for USD19.3 Million 12
KHB Shanghai Kehua Bio-Engineering Acquires Technogenetics USD20.6 Million 13
Shanghai Kehua to Acquire Technogentics from Bouty Healthcare 14
Shanghai Kehua Bio-engineering Co Ltd, Key Competitors 15
Shanghai Kehua Bio-engineering Co Ltd, Key Employees 16
Shanghai Kehua Bio-engineering Co Ltd, Subsidiaries 17

List of Figures
Shanghai Kehua Bio-engineering Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Shanghai Kehua Bio-engineering Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Shanghai Kehua Bio-engineering Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Shanghai Kehua Bio-engineering Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Shanghai Kehua Bio-engineering Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Shanghai Kehua Bio-engineering Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Shanghai Kehua Bio-engineering Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Shanghai Kehua Bio-engineering Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Shanghai Kehua Bio-engineering Co Ltd, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Shanghai Kehua Bio-engineering Co Ltd (002022):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • MEC Resources Ltd (MMR):企業の財務・戦略的SWOT分析
    MEC Resources Ltd (MMR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Citigroup Inc:戦略・SWOT・企業財務分析
    Citigroup Inc - Strategy, SWOT and Corporate Finance Report Summary Citigroup Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Tanabe Research Laboratories USA Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Tanabe Research Laboratories USA Inc (Tanabe Research Laboratories USA), a subsidiary of Mitsubishi Tanabe Pharma Corp is a healthcare research center that discovers and develops biological drugs. The laboratory conducts research on metabolics, immunology and inflammation. Its products are u …
  • Imperial Oil Ltd (IMO):石油・ガス:M&Aディール及び事業提携情報
    Summary Imperial Oil Ltd (Imperial Oil), a subsidiary of Exxon Mobil Corporation, is an integrated energy company. It is present across the value chain in petroleum industry including the exploration, production and sale of crude oil and natural gas. The company explores for and produces crude oil, …
  • Implenia AG:戦略・SWOT・企業財務分析
    Implenia AG - Strategy, SWOT and Corporate Finance Report Summary Implenia AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Orchids Paper Products Co (TIS):企業の財務・戦略的SWOT分析
    Orchids Paper Products Co (TIS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Chubu Electric Power Co Inc (9502)-石油・ガス分野:企業M&A・提携分析
    Summary Chubu Electric Power Co Inc (Chubu) is an energy utility. It generates and procures electricity; and offers electric network related services. The company produces electricity from nuclear, hydro, solar, biomass, wind, coal, fuel oil, and natural gas sources. Chubu has interests in upstream …
  • Knight Therapeutics Inc (GUD):企業の財務・戦略的SWOT分析
    Summary Knight Therapeutics Inc (Knight Therapeutics) focuses on acquisition, licensing, marketing and distribution of prescription, consumer health products and medical devices. The company offers tablets to treat metabolic, renal diseases and cancer; and injections against chronic pain and hormone …
  • Dermira Inc (DERM):企業の財務・戦略的SWOT分析
    Summary Dermira Inc (Dermira) is a biopharmaceutical company that identifies, develops and commercializes therapeutic solutions for the treatment of dermatologic diseases, such as hyperhidrosis, acne vulgaris and atopic dermatitis. The company’s product includes QBREXZA (glycopyrronium) cloth, an an …
  • Dynavax Technologies Corp (DVAX):企業の財務・戦略的SWOT分析
    Dynavax Technologies Corp (DVAX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Memphasys Ltd (MEM):医療機器:M&Aディール及び事業提携情報
    Summary Memphasys Ltd (Memphasys), formerly Nusep Holdings Ltd, is a bio-separations company that develops and commercializes membrane technology solutions. The company develops felix, a non-DNA damaging lab instrument for sperm separation that separates sperm from semen sample using electrophoresis …
  • Accugenomics Inc:企業の製品パイプライン分析
    Summary Accugenomics Inc (Accugenomics) is a developer of oncology molecular diagnostics. The company develops and markets gene expression tests to diagnose and monitor cancer treatment. It offers gene expression tests including lung cancer risk test, standardized BCR-ABL molecular diagnostics test …
  • Chiesi USA Inc:企業の戦略的SWOT分析
    Chiesi USA Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Xencor Inc (XNCR):企業の財務・戦略的SWOT分析
    Summary Xencor Inc (Xencor) is a clinical-stage biopharmaceutical company that develops engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer. The company provides pipeline products under preclinical development such as XmAb14045, for the …
  • Yomeishu Seizo Co Ltd (2540):企業の財務・戦略的SWOT分析
    Yomeishu Seizo Co Ltd (2540) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • TSI Holdings Co Ltd:企業の戦略・SWOT・財務分析
    TSI Holdings Co Ltd - Strategy, SWOT and Corporate Finance Report Summary TSI Holdings Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Lenovo Group Ltd (992):企業の財務・戦略的SWOT分析
    Lenovo Group Ltd (992) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Fresenius Kabi USA LLC-製薬・医療分野:企業M&A・提携分析
    Summary Fresenius Kabi USA LLC (Fresenius Kabi), a subsidiary of Fresenius Kabi AG, is a pharmaceutical and medical device company which provides lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. It provides products and services to critically and chronically il …
  • Linamar Corporation:企業の戦略・SWOT・財務情報
    Linamar Corporation - Strategy, SWOT and Corporate Finance Report Summary Linamar Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Camping World Holdings, Inc. (CWH):企業の財務・戦略的SWOT分析
    Camping World Holdings, Inc. (CWH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆